HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2019-12-17 (expresspharma.in)
Hetero launches TAFFIC, the latest 3-in-1 single pill for HIV treatment.
The 3-in-1 combination drug helps to prevent HIV from multiplying and works together to decrease the amount of HIV in the patient’s blood to undetectable levels
Read more
2018-02-27 (expresspharma.in)
Hetero launches TAFERO-EM
It is an anti-retroviral medication which is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection
Read more
2018-01-04 (centerforbiosimilars.com)
Indian Drug Maker Hetero Launches Adalimumab Biosimilar, Mabura
Today, Indian drug maker Hetero launched a biosimilar of adalimumab (referenced on Humira, made by AbbVie) to be marketed in India under the name Mabura. This is the fourth biosimilar Hetero has brought to the Indian market.
Read more
(economictimes.com)
Hetero launches generic breast cancer treatment drug in India
Drug firm Hetero Friday said it has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in the country.
Read more
(fiercepharma.com)
India's Hetero launches Avastin biosimilar, following Reliance into the market
Hyderabad-based Hetero Drugs has launched a biosimilar of Roche's ($RHHBY) colorectal cancer therapy Avastin (bevacizumab) in India, apparently overcoming a legal challenge by the Big Pharma linked | Hetero Drugs has launched a biosimilar of colorectal cancer therapy Avastin (bevacizumab) in India, apparently overcoming a legal challenge by Roche linked to language on the packaging label.
Read more
(indiatimes.com)
Hetero launches FDC combination of key HIV drugs
The FDC drug ‘Darunavir+Ritonavir is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients.
Read more
(economictimes.com)
Hetero launches biosimilar Rituximab in India
Hyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.
Read more
(indiatimes.com)
Hetero launches generic breast cancer treatment drug in India
Drug firm Hetero Friday said it has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in the country.
Read more